admin

Angry protesters disrupted a Tuesday hearing on Capitol Hill during which Health and Human Services Secretary Robert F. Kennedy Jr. testified about how the agency’s 2026 budget aligns with President Donald Trump’s agenda.  Kennedy did…

Rep. Bonnie Watson Coleman got into a heated exchange with Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on Wednesday, which culminated in the New Jersey Democrat declaring Kennedy’s ‘legitimacy’ as a health…

Director of National Intelligence Tulsi Gabbard moved the Presidential Daily Brief staff from the CIA to the Office of the Director of National Intelligence, Fox News Digital confirmed.  A senior intelligence source told Fox News…

It’s hard enough to know what you want. It’s even harder to know what others want. But what if what you want hinges on what somebody else wants…and they aren’t sure what they want? Hence the conundrum…

When oil prices plunged to four-year lows this year, many analysts immediately turned to the inflation narrative, dusting off the long-held belief that where oil prices go, inflation follows. But this time, the correlation isn’t…

Brightstar Resources (BTR:AU) has announced May Production Update – Processing Underway Download the PDF here. This post appeared first on investingnews.com

Errawarra Resources Ltd (ASX: ERW) is pleased to advise that recent surface sampling at its Elizabeth Hill Project has returned multiple elevated portable XRF (pXRF) silver (Ag) readings including high grade results up to 920g/t…

(TheNewswire) VANCOUVER, BC, May 14, 2025 TheNewswire – Heritage Mining Ltd. (CSE: HML) (‘ Heritage ‘ or the ‘ Company ‘) is pleased to announce that, further to its news release dated May 7, 2025,…

Eric Nuttall, partner and senior portfolio manager at Ninepoint Partners, shares his outlook for oil and natural gas, honing in on supply, demand and prices. Global uncertainty has placed pressure on the oil market, and…

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib…